← 返回

KCa3.1 通道调控头颈部癌中功能健全 NK 细胞的肿瘤浸润

英文原题:KCa3.1 channels regulate the tumor infiltration of functionally competent NK cells in head and neck cancer.

查看英文原题

KCa3.1 channels regulate the tumor infiltration of functionally competent NK cells in head and neck cancer.

PubMed 2025/10/17(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD8+ T细胞和自然杀伤(NK)细胞是抵御肿瘤细胞的主要防线。肿瘤微环境会削弱它们的抗肿瘤能力,包括浸润肿瘤的能力。本实验室此前发现,肿瘤可抑制KCa3.1钾通道活性,从而抑制T细胞;该通道调节细胞因子释放、细胞毒性和趋化性。

然而,钾通道在NK细胞抗肿瘤活性中的作用尚不清楚。本研究考察了KCa3.1通道在人头颈部鳞状细胞癌(HNSCC)NK细胞功能中的作用。使用TRAM-34选择性阻断KCa3.1,可抑制健康供者及HNSCC患者来源NK细胞的趋化;而药理学激活KCa3.1则增强趋化和细胞毒性。在人源化HNSCC小鼠模型中,SKA-31这一选择性KCa3.1激活剂增强了抗肿瘤免疫应答;该模型通过将Cal27细胞和健康供者外周血单个核细胞植入免疫缺陷小鼠构建。SKA-31治疗使肿瘤中的NK细胞总数增加7倍,功能活跃的颗粒酶B阳性NK细胞增加23倍。这些数据凸显了KCa3.1通道在抗肿瘤免疫中的关键作用,并提示靶向KCa3.1有望为HNSCC开发新型免疫疗法。

展开英文摘要原文

CD8 + T cells and natural killer (NK) cells are the primary defenses against tumor cells. The tumor microenvironment impairs their antitumor capabilities, including the ability to infiltrate the tumor.

Our laboratory has shown that tumors suppress T cells by inhibiting KCa3. 1 K + channel activity that controls cytokine release, cytotoxicity, and chemotaxis.

However, little is known about the role of K + channels in the anti-tumor activity of NK cells.

Here, we investigated KCa3. 1 channels' role in human NK cell function in head and neck squamous cell carcinoma (HNSCC). Selective blockade of KCa3. 1 using TRAM-34 inhibited chemotaxis of NK cells from both healthy donors and patients with HNSCC, while KCa3. 1pharmacological activation increased chemotaxis and cytotoxicity. SKA-31, a selective KCa3.

1 activator, enhanced antitumor immune responses in a humanized HNSCC mouse model generated by implanting Cal27 cells and healthy donor peripheral blood mononuclear cells into immunodeficient mice. SKA-31 treatment resulted in a 7-fold increase in total NK cells and a 23-fold increase in functionally active (granzyme B-positive) NK cells in these tumors. These data highlight the critical role of KCa3. 1 channels in antitumor immunity and open the possibility of targeting KCa3. 1 to develop new immunotherapies for HNSCC.

论文信息

作者
Alshwimi AO、Chimote AA、Khodoun MV、Weatherford L、Hinrichs BH、Wulff H、Waggoner SN、Wise-Draper TM
第一作者单位
Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.United States
通讯作者单位
Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA. laura.conforti@uc.edu.United States
期刊
Scientific reports2025 Oct 17
原文标识
PubMed 41107295 · DOI 10.1038/s41598-025-20101-x